Online citations, reference lists, and bibliographies.

Long-term Survival In Patients With Epithelial Ovarian Cancer Following Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

O. Le Saux, E. Decullier, G. Freyer, O. Glehen, N. Bakrin
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Objective: Despite a high response rate to first-line therapy, prognosis of epithelial ovarian carcinoma (EOC) remains poor. The objective of the present study was to evaluate the frequency of long-term survivors and to identify the prognostic factors associated with long-term survival in a French cohort of 566 patients. Methods: Patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for EOC in 13 French centers between 1991 and 2010 were included. Long-term survivors were defined as patients who survived more than 5 years after HIPEC and CRS, irrespective of relapse. Results: Seventy-eight long-term survivors were analyzed. The median follow-up was 74 months. Median age at the time of first HIPEC was 55.4 years (range [22.6–77.6]. Seven patients had advanced EOC and 71 patients had recurrent EOC (37 patients had platinum-resistant EOC and 32 had platinum-sensitive disease). More than half of the long-term survivors had high-grade serous ovarian cancer (HGSOC). In univariate analysis, age ≥50 years (p = .004), peritoneal cancer index (PCI) ≤ 8 (p = .049) and CA-125 < 100 (p = .02) were associated with long-term survival. There was a trend towards an association between higher CC-score and long-term survival (p = .057). Conclusion: Age ≥50 years, PCI ≤8 and CA125 < 100 were associated with long-term survival in univariate analysis. There was a trend towards the significance of CC-score. Platinum-status was not associated with long-term survival.
This paper references
10.1200/JCO.2008.16.1703
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
D. S. Tan (2008)
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
10.1097/IGC.0b013e31823eed2c
Long-Term Clinical Outcome of Patients With Recurrent Epithelial Ovarian Carcinoma: Is it the Same for Each Histological Type?
Hiroaki Kajiyama (2012)
Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant 648 O. LE SAUX ET AL. and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients
E Cotte (2007)
10.1002/jso.20686
Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.
M. Fleisch (2007)
10.1245/s10434-014-4157-9
Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
J. Spiliotis (2014)
10.1016/0090-8258(89)90114-5
Predictive factors for long-term survival in patients with advanced ovarian cancer.
K. J. Krag (1989)
10.1245/s10434-009-0878-6
Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer
PhD Facs Wim P. Ceelen MD (2009)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
A. Heintz (2006)
10.1016/j.ygyno.2017.10.032
Who are the long-term survivors of high grade serous ovarian cancer?
Claire Hoppenot (2018)
Oncogene expression: longterm compared with short-term survival in patients with advanced epithelial ovarian cancer
BA Goff (1998)
10.1200/JCO.2007.11.6905
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
A. Chetrit (2008)
Cancer of the ovary.
M. McKay (1994)
10.1016/0090-8258(90)90042-J
Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study.
K. Bertelsen (1990)
10.2174/138161212802002616
Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.
S. Mulier (2012)
10.1016/j.ygyno.2011.04.008
HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.
Anna Fagotti (2011)
10.1016/S0020-7292(06)60033-7
Carcinoma of the Ovary.
A. Heintz (2006)
10.1007/s00268-007-9146-8
Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients
E. Cotte (2007)
10.1016/S0029-7844(98)00121-5
Oncogene Expression: Long‐Term Compared With Short‐Term Survival in Patients With Advanced Epithelial Ovarian Cancer
B. Goff (1998)
10.1016/S0029-7844(98)00334-2
Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.
S. Rubin (1999)
10.1016/j.ejso.2013.09.030
Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
N. Bakrin (2013)
10.1007/s10147-014-0687-1
Clinical features of long-term survivors of recurrent epithelial ovarian cancer
H. Iwase (2014)
10.1200/JCO.2003.06.139
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.
O. Glehen (2003)
10.1002/14651858.CD007822.pub2
Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.
K. Galaal (2010)
10.1200/JCO.2013.51.4489
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
E. Pujade-Lauraine (2014)
10.1016/j.ygyno.2012.11.018
Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.
J. N. Barlin (2013)
10.1016/J.EJCA.2006.06.026
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors.
K. Partheen (2006)
10.1016/j.ygyno.2008.08.033
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
R. Bristow (2009)
10.1097/IGC.0000000000000721
An Integrative Genomic Analysis of Formalin Fixed Paraffin-Embedded Archived Serous Ovarian Carcinoma Comparing Long-term and Short-term Survivors
K Stålberg (2016)
10.1245/s10434-012-2446-8
Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer
PhD Suk-Joon Chang MD (2012)
10.1158/1078-0432.CCR-04-2398
Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers
A. Berchuck (2005)
10.2174/092986707782360079
Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins.
C. Didelot (2007)
Ten years survival of FIGO stage IIIC epithelial ovarian cancer cases due to lymph node metastases only.
E. Grossi (2012)
10.1245/s10434-015-5050-x
Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
M. Petrillo (2015)
10.1200/JCO.2006.10.2517
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
W. Winter (2007)
10.1155/2013/672873
Hyperthermia versus Oncothermia: Cellular Effects in Complementary Cancer Therapy
G. Hegyi (2013)
10.1056/NEJMoa1708618
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
W. V. van Driel (2018)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
10.1002/jso.21491
Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction.
Weiqi Tian (2010)
10.1093/annonc/mdq577
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
D. Gallagher (2011)
10.1097/IGC.0000000000000653
Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer
K. Albuquerque (2016)
10.1111/J.1525-1438.2005.00185.X
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short‐ and long‐term survivors?
J. Kaern (2005)
10.21873/ANTICANRES.11110
What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature.
Ziad Hilal (2016)
10.1016/0169-5002(95)00594-3
Long-term survival in small cell lung cancer: the case for a standard definition
R. Stephens (1996)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar